NASDAQ:STIM Neuronetics (STIM) Stock Price, News & Analysis $1.79 +0.01 (+0.56%) (As of 09:30 AM ET) Add Compare Share Share Today's Range$1.79▼$1.7950-Day Range$1.73▼$3.8152-Week Range$1.03▼$5.07Volume1,333 shsAverage Volume173,182 shsMarket Capitalization$53.70 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Neuronetics alerts: Email Address Neuronetics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside346.9% Upside$8.00 Price TargetShort InterestHealthy0.30% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.33Based on 2 Articles This WeekInsider TradingAcquiring Shares$102,500 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.91) to ($0.61) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.01 out of 5 starsMedical Sector356th out of 896 stocksSurgical & Medical Instruments Industry46th out of 96 stocks 3.5 Analyst's Opinion Consensus RatingNeuronetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNeuronetics has only been the subject of 1 research reports in the past 90 days.Read more about Neuronetics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.30% of the outstanding shares of Neuronetics have been sold short.Short Interest Ratio / Days to CoverNeuronetics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neuronetics has recently decreased by 6.31%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeuronetics does not currently pay a dividend.Dividend GrowthNeuronetics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for STIM. Previous Next 1.9 News and Social Media Coverage News SentimentNeuronetics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Neuronetics this week, compared to 2 articles on an average week.Search Interest1 people have searched for STIM on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Neuronetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neuronetics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $102,500.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 9.80% of the stock of Neuronetics is held by insiders.Percentage Held by Institutions53.59% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neuronetics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Neuronetics are expected to grow in the coming year, from ($0.91) to ($0.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neuronetics is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neuronetics is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuronetics has a P/B Ratio of 1.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Neuronetics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About Neuronetics Stock (NASDAQ:STIM)Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.Read More STIM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STIM Stock News HeadlinesJune 7, 2024 | insidertrades.comRobert Cascella Purchases 50,000 Shares of Neuronetics, Inc. (NASDAQ:STIM) StockJuly 1, 2024 | globenewswire.comNeuroStar® Launches Better Me Provider Program NationwideJuly 5, 2024 | Behind the Markets (Ad)"The Biggest Drug Ever" Is ComingUBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Pharma's biggest blockbuster yet." Bank of America predicts it will be the world's first "$100 billion dollar a year drug." And Morgan Stanley predicts 250 million prescriptions will be written each year.June 13, 2024 | globenewswire.comNeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual MeetingMay 24, 2024 | msn.comNeuronetics to Present at William Blair Growth ConferenceMay 23, 2024 | globenewswire.comNeuronetics to Present at the William Blair 44th Annual Growth Stock ConferenceMay 15, 2024 | msn.comWilliam Blair Upgrades Neuronetics (STIM)May 15, 2024 | globenewswire.comHumana Is First Commercial Payer to Address TMS Therapy Coverage for AdolescentsJuly 5, 2024 | Behind the Markets (Ad)"The Biggest Drug Ever" Is ComingUBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Pharma's biggest blockbuster yet." Bank of America predicts it will be the world's first "$100 billion dollar a year drug." And Morgan Stanley predicts 250 million prescriptions will be written each year.May 10, 2024 | msn.comNeuronetics Boasts 12% Revenue Increase, Expands Depression Treatment SectorMay 9, 2024 | finance.yahoo.comNeuronetics, Inc. (NASDAQ:STIM) First-Quarter Results: Here's What Analysts Are Forecasting For This YearMay 9, 2024 | seekingalpha.comNeuronetics: Reality Set InMay 8, 2024 | markets.businessinsider.comStrong Buy Rating for Neuronetics Backed by Solid Financials and Growth ProspectsMay 8, 2024 | finance.yahoo.comNeuronetics, Inc. (NASDAQ:STIM) Q1 2024 Earnings Call TranscriptMay 8, 2024 | markets.businessinsider.comBuy Rating on Neuronetics: Solid Fundamentals and Growth Despite ChallengesMay 8, 2024 | finance.yahoo.comNeuronetics Inc (STIM) (Q1 2024) Earnings Call Transcript Highlights: Strategic Growth Amidst ...May 8, 2024 | wsj.comNeuronetics Inc.May 7, 2024 | msn.comNeuronetics GAAP EPS of -$0.27 beats by $0.04, revenue of $17.42M beats by $0.3MMay 7, 2024 | msn.comSTIM Stock Earnings: Neuronetics Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | finance.yahoo.comNeuronetics Inc (STIM) Reports Q1 2024 Earnings: Revenue Surpasses Estimates, Narrowing LossesMay 7, 2024 | globenewswire.comNeuronetics Reports Record First Quarter 2024 Financial and Operating ResultsMay 6, 2024 | msn.comNeuronetics Q1 2024 Earnings PreviewMay 4, 2024 | finance.yahoo.comNeuronetics, Inc. (STIM)May 4, 2024 | msn.comNeuronetics Awards Stock Options to New Employees as InducementMay 3, 2024 | globenewswire.comNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 1, 2024 | globenewswire.comNeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness MonthApril 25, 2024 | msn.comNeuronetics Announces Q1 2024 Earnings Release and Conference CallSee More Headlines Receive STIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/05/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:STIM CUSIPN/A CIK1227636 Webwww.neurostar.com Phone(610) 640-4202Fax610-640-4206Employees203Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+349.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,190,000.00 Net Margins-37.61% Pretax Margin-37.61% Return on Equity-75.84% Return on Assets-26.67% Debt Debt-to-Equity Ratio2.15 Current Ratio5.65 Quick Ratio5.18 Sales & Book Value Annual Sales$71.35 million Price / Sales0.75 Cash FlowN/A Price / Cash FlowN/A Book Value$1.18 per share Price / Book1.51Miscellaneous Outstanding Shares30,000,000Free Float27,058,000Market Cap$53.40 million OptionableOptionable Beta2.32 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Keith J. Sullivan (Age 66)President, CEO & Director Comp: $1.39MMr. Stephen J. Furlong M.S. (Age 60)Executive VP, CFO & Treasurer Comp: $771.38kMr. W. Andrew Macan (Age 51)Executive VP, GC, Chief Compliance Officer & Corporate Secretary Comp: $629.7kMr. Rusty PageSenior VP of Operations & QualityMs. Lisa Metzner-RosasSenior VP & Chief Marketing OfficerMs. Sara GrubbsSenior VP & Chief Revenue OfficerMr. Rick GrubbsSenior Vice President of National AccountsMr. Cory S. AndersonSenior Vice President of R&D and ClinicalMore ExecutivesKey CompetitorsPolyPidNASDAQ:PYPDLyra TherapeuticsNASDAQ:LYRANeuroPaceNASDAQ:NPCEAVITA MedicalNASDAQ:RCELAccurayNASDAQ:ARAYView All CompetitorsInsiders & InstitutionsRobert CascellaBought 50,000 shares on 6/6/2024Total: $102,500.00 ($2.05/share)Silvercrest Asset Management Group LLCBought 51,881 shares on 5/16/2024Ownership: 3.928%Kent Lake Capital LLCSold 94,890 shares on 5/16/2024Ownership: 3.404%FourWorld Capital Management LLCBought 35,921 shares on 5/16/2024Ownership: 0.120%Vanguard Group Inc.Sold 53,229 shares on 5/10/2024Ownership: 4.337%View All Insider TransactionsView All Institutional Transactions STIM Stock Analysis - Frequently Asked Questions Should I buy or sell Neuronetics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" STIM shares. View STIM analyst ratings or view top-rated stocks. What is Neuronetics' stock price target for 2024? 2 brokerages have issued 1 year target prices for Neuronetics' stock. Their STIM share price targets range from $8.00 to $8.00. On average, they expect the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 346.9% from the stock's current price. View analysts price targets for STIM or view top-rated stocks among Wall Street analysts. How have STIM shares performed in 2024? Neuronetics' stock was trading at $2.90 at the beginning of the year. Since then, STIM shares have decreased by 38.3% and is now trading at $1.79. View the best growth stocks for 2024 here. When is Neuronetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our STIM earnings forecast. How were Neuronetics' earnings last quarter? Neuronetics, Inc. (NASDAQ:STIM) posted its quarterly earnings results on Tuesday, May, 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.06. The firm earned $17.42 million during the quarter, compared to analysts' expectations of $17.10 million. Neuronetics had a negative trailing twelve-month return on equity of 75.84% and a negative net margin of 37.61%. What guidance has Neuronetics issued on next quarter's earnings? Neuronetics updated its second quarter 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $18.0 million-$19.0 million, compared to the consensus revenue estimate of $19.5 million. What other stocks do shareholders of Neuronetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), iBio (IBIO), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST). When did Neuronetics IPO? Neuronetics (STIM) raised $75 million in an initial public offering on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair acted as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers. How do I buy shares of Neuronetics? Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:STIM) was last updated on 7/5/2024 by MarketBeat.com Staff From Our PartnersUrgent Alert: Is the U.S. Implementing a Digital Dollar?Our exclusive guide, "Exploring the Future of the U.S. Dollar in a Digital World," is your essential resource ...Gold Gate Capital | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredDOLLAR RECALL ON THE AGENDAHave you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming...Golden Crest | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuronetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuronetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.